Ascensus Specialties, a provider of speciality materials for life sciences and advanced technology, has followed up on previous acquisitions by buying fine chemicals manufacturer Wychem from private equity firm Aurelius, which had acquired it in 2016. The company employs 25 people at its site in the UK.
CDMO CordenPharma is planning to invest heavily in all its platforms in terms of both capacities and capabilities, according to Dr Stephen Houldsworth, global head of platform management and marketing, who spoke with SCM at CPhI Worldwide in Milan.
CDMO Sterling Pharma Solutions has announced what it called the next phase of a multi-year investment strategy at its site in Dudley, UK. It will spend £10 million by mid-2022 on new process development laboratories and commercial-scale manufacturing equipment to meet growth in demand for small molecule API manufacturing.
CDMO Hovione used CPhI Worldwide 2021 in Milan to announce plans to invest $170 million over the years 2020-2022 to expand both capacities and capabilities at three sites in Portugal, Ireland, and New Jersey. About 300 jobs will be created as a result. These reflect its increasing focus on spray drying, high potency and particle engineering.
Flamma USA, the North American arm of the Italian CDMO, has completed the re-commissioning of the HPAPI suite at its site at Malvern, Pennsylvania, following an “exhaustive qualification” over the past six months. This is meant to be a viable alternative for customers early stage HPAPIs when lead times are long for others.
At CPhI Worldwide 2021 in Milan on 9-11 November, Italian CDMO Olon announced “a significant expansion of its pipeline of APIs, a result of its R&D investment strategy”. In all, it has added nine new active substances for the generics market by investing across several lines and at multiple facilities in its network.
Indian chlor-alkali producer Meghmani Finechem is to spend €21.6 million to expand into the chlorotoluene value chain at its site in Dahej, Gujarat. Due to be commissioned by Q4 2024, this will be the first plant in India to be back-integrated into toluene chlorination, and will produce pharmaceutical and agrochemical intermediates.
